AyuVis

Fort Worth’s AyuVis Gets FDA Fast‑Track Designation for Its Drug for Babies with a Chronic Lung Disease

by | Aug 23, 2024
Premature babies diagnosed with bronchopulmonary dysplasia (BPD) face the risk of rehospitalization, delayed brain development, and respiratory problems throughout childhood. No FDA-approved therapies are available for BPD—which is why the new FDA designation for AyuVis's drug candidate, AVR-48, could lead to game-changing impact.
MORE
Follow the Money: OxeFit Lands New Celebrity Backers, Dallas Biotech Raises $10M to Fight Cancer, Blockchain Investor Raises New Fund-of-Funds, and More
by | May 17, 2022
What companies are finding funding or having a big exit? From startup investments to grants and acquisitions, Dallas Innovates tracks what’s happening in North Texas money.
MORE
Fort Worth Immunotherapy Startup Gets $1.8M Grant Ahead of First Clinical Trials
by | May 12, 2022
AyuVis, an immunotherapy startup, is set to get a $1.8 million Small Business Innovation Research grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The funding will support the pre-clinical research of its drug candidate to treat the second-leading cause of death in premature babies.

Founder Suchismita Acharya calls the timing "perfect."
MORE